Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA® (sodium zirconium cyclosilicate) to include a dosing ...
—European investigators examined pretransplant plasma potassium levels and the need for potassium-lowering interventions to resolve hyperkalemia within 48 hours after kidney transplantation. Chronic ...
Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure. Cardiorenal risks increase following discontinuation or downtitration of ...
Please provide your email address to receive an email when new articles are posted on . The National Kidney Foundation launched a public education video series about hyperkalemia for patients with ...
Patiromer was well tolerated in patients with nondialysis-dependent chronic kidney disease stages 1 to 5. Patiromer, a sodium-free potassium binder, effectively treats hyperkalemia at any stage of ...
If you have hyperkalemia, you have high levels of potassium in your blood. If you don’t get your potassium under control, the condition can be life-threatening. That’s why it’s important to advocate ...
patient lying down during dialysis session in hospital Modifying the potassium concentration used for dialysis may decrease mortality risk among hospitalized patients with end-stage kidney disease and ...
It can be administered orally or in an enema. ANI Pharmaceuticals announced the launch of Kionex ® (sodium polystyrene sulfonate suspension USP) for Oral or Rectal Use for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback